Round 1 | p Value* | Round 2 | p Value† | Round 3 | p Value‡ | Round 4 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
n | Per cent | n | Per cent | n | Per cent | n | Per cent | ||||
0.01 | 0.001 | 0.06 | |||||||||
Histology | |||||||||||
Adenocarcinoma | 35 | 47.3 | 35 | 60.3 | 37 | 48.1 | 23 | 50.0 | |||
Squamous cell carcinoma | 15 | 20.3 | 3 | 5.2 | 16 | 20.8 | 10 | 21.7 | |||
BAC | 2 | 2.7 | 3 | 5.2 | 6 | 7.8 | 4 | 8.7 | |||
SCLC | 1 | 1.4 | 2 | 3.4 | 5 | 6.5 | 3 | 6.5 | |||
NSCLC, not specified | 2 | 2.7 | – | – | – | – | 4 | 8.7 | |||
Others | 19§ | 25.7 | 15¶ | 25.9 | 13** | 16.9 | 2†† | 4.3 | |||
Total | 74 | 100 | 58 | 100 | 77 | 100 | 46 | 100 |
*p Value: difference in histology between the first and last screening rounds. Fisher's exact test was used.
†p Value: difference in histology between the second and last screening rounds. Fisher's exact test was used.
‡p Value: difference in histology between the third and last screening rounds. Fisher's exact test was used.
§Others in round 1: 5 large cell carcinomas, 1 mixed NSCLC/SCLC, 4 carcinoids, 1 other, 3 no diagnosis was possible, 2 adenosquamous and 3 large-cell neuroendocrine carcinoma.
¶Others in round 2: 10 large-cell carcinomas, 2 adenosquamous cell carcinoma and 3 cancers without a diagnosis were included in the group of others; in round 4: 2 cancers without a possible diagnosis were included in the group of others.
**Others in round 3: 2 large-cell carcinomas, 1 mixed NSCLC/SCLC, 2 carcinoids, 1 large-cell neuroendocrine carcinoma and 7 without a diagnosis; in round 4: 2 cancers without a diagnosis.
††Others in round 4: 2 with no diagnosis possible. No other types of lung cancers were detected in this round.
BAC: bronchoalveolar carcinoma; NSCLC, non-small cell lung carcinoma; SCLC: small-cell carcinoma.